4. Correlation between apolipoprotein b/a1 and the risk of metabolic-related fatty liver disease depending on the lipid profile

Авторы

DOI:

https://doi.org/10.35805/BSK2025I004

Загрузки

Аннотация

Background. The aim of this study was to investigate the relationship between the Apolipoprotein B/Apolipoprotein A1 ratio and the risk of metabolically associated fatty liver disease, considering lipid profile variations and determine whether the Apolipoprotein B/Apolipoprotein A1 ratio can serve as an independent predictor of metabolically associated fatty liver disease and its associated cardiovascular risks.

Methods. A total of 377 patients diagnosed with cardiovascular disease and coexisting metabolically associated fatty liver disease were stratified into high-risk and very high-risk groups based on established clinical and imaging criteria. Lipid profiles, Apolipoprotein B, and Apolipoprotein A1 levels were measured, and their associations with cardiovascular and metabolic parameters were analyzed using correlation and regression models.

Results. The findings reveal a strong positive correlation between Apolipoprotein B levels and atherogenic lipid markers such as low-density lipoproteins cholesterol and total cholesterol, as well as a moderate correlation with triglycerides. In contrast, Apolipoprotein A1 demonstrated a strong positive association with high-density lipoproteins cholesterol and an inverse correlation with metabolic indicators such as Hemoglobin A1c and glucose, suggesting a potential protective role. The Apolipoprotein B/Apolipoprotein A1 ratio emerged as a more accurate predictor of cardiovascular and metabolic risk than traditional lipid ratios. Furthermore, the Apolipoprotein B/Apolipoprotein A1 ratio was significantly associated with the presence and severity of metabolically associated fatty liver disease, reinforcing its potential utility as a biomarker for metabolic liver disease.

Conclusion. This study highlights the clinical relevance of incorporating apolipoprotein measurements into the routine assessment of individuals at risk for metabolic and cardiovascular disease.

Ключевые слова

Apolipoprotein B, Apolipoprotein A1, metabolic-associated fatty liver disease, cardiovascular disease, lipid metabolism, dyslipidemia, risk assessment

Библиографические ссылки

  1. Khandouzi N, Shidfar F, Rajab A, Rahideh T, Hosseini P, Mir Taheri M. The effects of ginger on fasting blood sugar, hemoglobin a1c, apoli-poprotein B, apolipoprotein a-I and malondialdehyde in type 2 diabetic patients. Iran J Pharm Res. Winter 2015;14(1):131-40
  2. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Dis-ease: A Narrative Review. JAMA Cardiol. Dec 1 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780
  3. Shapiro MD, Fazio S. Apolipoprotein B-containing lipoproteins and ath-erosclerotic cardiovascular disease. F1000Res. 2017;6:134. doi:10.12688/f1000research.9845.1
  4. Mehta A, Shapiro MD. Apolipopro-teins in vascular biology and athero-sclerotic disease. Nat Rev Cardiol. Mar 2022;19(3):168-179. doi:10.1038/s41569-021-00613-5
  5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global ep-idemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. Jul 2016;64(1):73-84. doi:10.1002/hep.28431
  6. Shang Y, Nasr P, Widman L, Hagstrom H. Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology. Nov 2022;76(5):1495-1505. doi:10.1002/hep.32519
  7. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steato-sis to fibrosing-steatohepatitis us-ing paired biopsies: implications for prognosis and clinical management. J Hepatol. May 2015;62(5):1148-55. doi:10.1016/j.jhep.2014.11.034
  8. Sun DQ, Jin Y, Wang TY, et al. MAFLD and risk of CKD. Metabolism. Feb 2021;115:154433. doi:10.1016/j.me-tabol.2020.154433
  9. Hassen G, Singh A, Belete G, et al. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Cureus. May 2022;14(5):e25495. doi:10.7759/cureus.25495
  10. Siddiqui MS, Fuchs M, Idowu MO, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic li-poprotein profile. Clin Gastroenterol Hepatol. May 2015;13(5):1000-8 e3. doi:10.1016/j.cgh.2014.10.008
  11. Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Manage-ment of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Dis-ease. Curr Atheroscler Rep. Jul 2022;24(7):533-546. doi:10.1007/s11883-022-01028-4
  12. Liao X, Ma Q, Wu T, et al. Lipid-Low-ering Responses to Dyslipidemia Determine the Efficacy on Liver En-zymes in Metabolic Dysfunction-As-
  13. Liu Y, Zhong GC, Tan HY, Hao FB, Hu JJ. Nonalcoholic fatty liver dis-ease and mortality from all causes, cardiovascular disease, and can-cer: a meta-analysis. Sci Rep. Jul 31 2019;9(1):11124. doi:10.1038/s41598-019-47687-3
  14. Sanyal AJ, Van Natta ML, Clark J, et al. Prospective Study of Out-comes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. Oct 21 2021;385(17):1559-1569. doi:10.1056/NEJMoa2029349
  15. Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Me-tabolism. Aug 2016;65(8):1109-23. doi:10.1016/j.metabol.2016.05.003
  16. Bril F, Cusi K. Management of Non-alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Diabetes Care. Mar 2017;40(3):419-430. doi:10.2337/dc16-1787
  17. Wang X, Zhang R, Yan C, Jin Y. As-sociation of Dietary Inflammation Index with sarcopenia in adult wom-en with nonalcoholic fatty liver dis-ease: based on the National Health and Nutrition Examination Sur-vey Database. Eur J Gastroenterol Hepatol. Dec 18 2024; doi:10.1097/MEG.0000000000002908
  18. Liu N, Li H. Influence of phytosomal curcumin on anthropometric indices for nonalcoholic fatty liver disease: A meta-analysis. Medicine (Balti-more). Dec 27 2024;103(52):e40538. doi:10.1097/MD.0000000000040538

Опубликован

2025-03-31

Выпуск

№ 1 (2025)

Раздел

Статьи